Press Releases on November 3, 2023 - EIN Presswire - Press Release Distribution Service

Published on November 3, 2023 - 16:00 GMT

CDR-Life Presents Findings from Two Studies in Preparation of Phase 1 Trial with Immunotherapy CDR404 for Treatment of Solid ...

Therapeutic potential of CDR404, as a first-of-its-kind precision immunotherapy for HLA-A*02:01+ patients with MAGE-A4+ squamous non-small cell lung carcinoma (SQ-NSCLC) Development of a Quantitative Systems Pharmacology (QSP) model to facilitate discovery …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Published on November 3, 2023 - 16:00 GMT

Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results

Press Release – No. 14 / 2023 Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results Copenhagen, Denmark, November 3, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on November 3, 2023 - 16:00 GMT

Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with ...

MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment MP0317 monotherapy shows a favorable safety profile up to the highest planned doses Patient recruitment of the study’s dose- …

Distribution channels: Culture, Society & Lifestyle ...

Published on November 3, 2023 - 16:00 GMT

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 ...

Overall response rate (ORR) of 47% and disease control rate (DCR) of 65% in first line (1L) recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® (pembrolizumab) ORR of 56% in patients with low expression of PD-L1 in the tumor Median …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on November 3, 2023 - 16:00 GMT

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society ...

Research Provides Early Validation of ALLO-182, an AlloCAR T™ Candidate in the IND-Enabling Phase of Development Targeting Claudin18.2 for the Treatment of Patients with Gastric and Pancreatic Cancers SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE …

Distribution channels: Conferences & Trade Fairs, Healthcare & Pharmaceuticals Industry ...

Published on November 3, 2023 - 16:00 GMT

Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid ...

First-in-human Phase 1 study demonstrates early clinical proof of concept Positive clinical biomarker data demonstrate evidence of immune system activation and the translation of the immunogenic response previously observed in preclinical studies Data …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Published on November 3, 2023 - 16:00 GMT

Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting

SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of …

Distribution channels: Healthcare & Pharmaceuticals Industry, Technology ...

Published on November 3, 2023 - 16:00 GMT

Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control

MARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Published on November 3, 2023 - 16:00 GMT

Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA

SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp® De novo Cloning and Amplification kit on the BioXp 3250 and …

Distribution channels: Media, Advertising & PR, Technology ...

Published on November 3, 2023 - 16:00 GMT

Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for ...

Cloak™ and Dagger™ Technologies Show Potential to Reduce Dependence on Standard Lymphodepletion and Enhance Performance of AlloCAR T™ Cells Data from Preclinical Study of Cloak™ Technology Highlights Ability to Engineer Allogeneic Cells to Evade Detection …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on November 3, 2023 - 16:00 GMT

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Media Release Statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed and linked to improved clinical outcomes Early increase in absolute …

Distribution channels: Technology ...

Published on November 3, 2023 - 16:00 GMT

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Clinical responses and durable activity with agenT-797 monotherapy and in combination with anti-PD-1 First-of-a-kind persistence for an allogeneic cell therapy, with agenT-797 detected for up to 6 months without toxic pre-conditioning AgenT-797 advancing …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on November 3, 2023 - 16:00 GMT

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary ...

– SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space – – BioCryst to host R&D Day today at 1:00 pm ET – ALPHARETTA, Ga. and RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...

Published on November 3, 2023 - 16:00 GMT

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic ...

Initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC) after experimental treatment with CAN-2409 Estimated overall survival rate was 71.4% at 36 months in CAN-2409 …

Distribution channels: Technology ...

Published on November 3, 2023 - 16:00 GMT

IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer ...

This data represents a step forward in developing next-generation ‘off-the-shelf’ iPSC derived gamma-delta T cells. Our proprietary expansion methods are serum and feeder-free and have the potential to produce billions of iVδ1 T cells. IN8bio's iVd1+ …

Distribution channels: Technology ...

Published on November 3, 2023 - 16:00 GMT

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab – - Integrated pharmacokinetic and clinical data analyses support the …

Distribution channels: Media, Advertising & PR, Technology ...

Published on November 3, 2023 - 16:00 GMT

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual ...

Company’s T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Published on November 3, 2023 - 16:00 GMT

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2,...

Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses (≥2.8 mg/kg) and 31% disease control rate across all dose levels in a range of solid tumor types, including cold tumors Treatment-related adverse events …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on November 3, 2023 - 16:00 GMT

LambdaTest Announces Exclusive Offer for Black Friday and Cyber Monday to Help Businesses be Sales Ready

San Francisco, Nov. 03, 2023 (GLOBE NEWSWIRE) -- LambdaTest, a leading cloud-based unified testing platform announced an exclusive offer to assist businesses in preparing for Black Friday sales day. As Black Friday and Cyber Monday approach, online …

Distribution channels: IT Industry, Media, Advertising & PR ...

Published on November 3, 2023 - 16:00 GMT

Solar Integrated Roofing Corp. Provides Corporate and Operational Update

HENDERSON, Nev., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Solar Integrated Roofing Corp. (OTC: SIRC) (“SIRC” or the Company”), an integrated, single-source solutions provider of solar power, roofing and EV charging systems CEO Brad Rinehart answers questions …

Distribution channels: Energy Industry ...